FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3132531605> ?p ?o ?g. }

• W3132531605 endingPage "07" @default.
• W3132531605 startingPage "GS1" @default.
• W3132531605 abstract "Abstract Systemic breast cancer treatments often fail to achieve complete and sustained responses due to drug-persistent residual tumor foci, the “seed” for eventual relapse. Recent clinical studies have revealed that the chemo-persistent tumor cells undergo extensive transcriptional reprogramming in response to neo-adjuvant treatment; however, the impact of this acquired molecular signature on the ability of residual cancer cells to survive during therapy is not clear. To further study the molecular hallmarks of chemo-persistent cancer cells, we analyzed the transcriptional signatures of post-treatment residual tumors in a large number of breast cancer patients from several neoadjuvant clinical studies. We observed that the treatment-persistent tumor cells had a distinct cellular state which molecularly resembles that of the embryonic diapause, a dormant stage of transiently suspended development in undifferentiated epiblasts triggered by stress and induced by suppression of Myc activity and overall biosynthesis. Remarkably, the propensity for residual tumors with an embryonic diapause-like (EDL) molecular signature was significantly associated with worse outcome in breast cancer patients. To dissect this distinct cancer cell state, we developed novel in vitro models using 3D breast cancer organoids which responded to cytotoxic treatment by generating longitudinally-persistent residual organoid fractions that phenotypically and molecularly simulated the in vivo emergence of post-treatment residual tumors in preclinical and clinical settings. The treatment-persistent tumor fractions in cancer organoids and in the respective in vivo xenografts did not exhibit significant genetic changes compared to baseline tumor cells, but had reduced apoptotic priming and an EDL transcriptional reprograming similar to that of residual tumors in patients. Similarly to embryonic diapause, residual persistent fractions in cancer organoids, xenografts and patient tumors had markedly suppressed Myc transcriptional output and biosynthetic levels. Ectopic induction of MYC expression enhanced acute chemotherapeutic cytotoxicity in breast cancer organoids. Conversely, suppression of MYC or pharmacological inhibition of Myc transcriptional co-activators, BET bromodomains, abrogated chemotherapeutic cytotoxicity and induced in breast cancer cells an EDL molecular signature characterized by below-baseline redox stress levels which were maintained during drug exposure. High-throughput interrogation of residual persistent breast cancer organoids indicated broad refractoriness to specific anticancer drug classes thought to operate through induction of cellular stress (e.g. agents targeting DNA or DNA-repair). However, maintaining the residual cells in dormancy after completion of cytotoxic chemotherapy via inhibition of Brd4/Myc axis or pharmacologically interfering with the diapause-like transcriptional reprogramming of treatment-persistent cancer cells represent potential therapeutic strategies to target chemo-persistent tumor cells. Overall, our study shows that breast tumors dynamically co-opt the stress survival mechanism of embryonic diapause to persist during treatment, and reveals an unexpected role of Myc as regulator of cancer cell entry into transient drug-refractory dormancy. The diapause-like persister organoid cancer models provide ex vivo tractability for studying the otherwise elusive, dormant, drug-refractory residual tumors, with potential implications in personalized medicine and drug discovery. Citation Format: Eugen Dhimolea, Ricardo De Matos Simoes, Dhvanir Kansara, Juliette Bouyssou, Jennifer Roth, Michal Sheffer, Rinath Jeselsohn, Nathanael Gray, Ulrich Steidl, Boris Bartholdy, Myles Brown, Aedin Culhane, Constantine Mitsiades. Treatment persistence of residual breast tumors through an embryonic diapause-like cancer cell state with suppressed myc activity [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr GS1-07." @default.
• W3132531605 created "2021-03-01" @default.
• W3132531605 creator A5005661878 @default.
• W3132531605 creator A5012712111 @default.
• W3132531605 creator A5022352605 @default.
• W3132531605 creator A5023112790 @default.
• W3132531605 creator A5032253351 @default.
• W3132531605 creator A5033532061 @default.
• W3132531605 creator A5045482909 @default.
• W3132531605 creator A5051714606 @default.
• W3132531605 creator A5053440456 @default.
• W3132531605 creator A5074250265 @default.
• W3132531605 creator A5077804779 @default.
• W3132531605 creator A5080568313 @default.
• W3132531605 creator A5082180580 @default.
• W3132531605 date "2021-02-15" @default.
• W3132531605 modified "2023-09-27" @default.
• W3132531605 title "Abstract GS1-07: Treatment persistence of residual breast tumors through an embryonic diapause-like cancer cell state with suppressed myc activity" @default.
• W3132531605 doi "https://doi.org/10.1158/1538-7445.sabcs20-gs1-07" @default.
• W3132531605 hasPublicationYear "2021" @default.
• W3132531605 type Work @default.
• W3132531605 sameAs 3132531605 @default.
• W3132531605 citedByCount "0" @default.
• W3132531605 crossrefType "journal-article" @default.
• W3132531605 hasAuthorship W3132531605A5005661878 @default.
• W3132531605 hasAuthorship W3132531605A5012712111 @default.
• W3132531605 hasAuthorship W3132531605A5022352605 @default.
• W3132531605 hasAuthorship W3132531605A5023112790 @default.
• W3132531605 hasAuthorship W3132531605A5032253351 @default.
• W3132531605 hasAuthorship W3132531605A5033532061 @default.
• W3132531605 hasAuthorship W3132531605A5045482909 @default.
• W3132531605 hasAuthorship W3132531605A5051714606 @default.
• W3132531605 hasAuthorship W3132531605A5053440456 @default.
• W3132531605 hasAuthorship W3132531605A5074250265 @default.
• W3132531605 hasAuthorship W3132531605A5077804779 @default.
• W3132531605 hasAuthorship W3132531605A5080568313 @default.
• W3132531605 hasAuthorship W3132531605A5082180580 @default.
• W3132531605 hasConcept C104317684 @default.
• W3132531605 hasConcept C121608353 @default.
• W3132531605 hasConcept C142724271 @default.
• W3132531605 hasConcept C143998085 @default.
• W3132531605 hasConcept C145103041 @default.
• W3132531605 hasConcept C1491633281 @default.
• W3132531605 hasConcept C207001950 @default.
• W3132531605 hasConcept C502942594 @default.
• W3132531605 hasConcept C530470458 @default.
• W3132531605 hasConcept C54355233 @default.
• W3132531605 hasConcept C71924100 @default.
• W3132531605 hasConcept C77255625 @default.
• W3132531605 hasConcept C86803240 @default.
• W3132531605 hasConcept C96232424 @default.
• W3132531605 hasConceptScore W3132531605C104317684 @default.
• W3132531605 hasConceptScore W3132531605C121608353 @default.
• W3132531605 hasConceptScore W3132531605C142724271 @default.
• W3132531605 hasConceptScore W3132531605C143998085 @default.
• W3132531605 hasConceptScore W3132531605C145103041 @default.
• W3132531605 hasConceptScore W3132531605C1491633281 @default.
• W3132531605 hasConceptScore W3132531605C207001950 @default.
• W3132531605 hasConceptScore W3132531605C502942594 @default.
• W3132531605 hasConceptScore W3132531605C530470458 @default.
• W3132531605 hasConceptScore W3132531605C54355233 @default.
• W3132531605 hasConceptScore W3132531605C71924100 @default.
• W3132531605 hasConceptScore W3132531605C77255625 @default.
• W3132531605 hasConceptScore W3132531605C86803240 @default.
• W3132531605 hasConceptScore W3132531605C96232424 @default.
• W3132531605 hasIssue "4_Supplement" @default.
• W3132531605 hasLocation W31325316051 @default.
• W3132531605 hasOpenAccess W3132531605 @default.
• W3132531605 hasPrimaryLocation W31325316051 @default.
• W3132531605 hasRelatedWork W1490655572 @default.
• W3132531605 hasRelatedWork W2224319365 @default.
• W3132531605 hasRelatedWork W2317782583 @default.
• W3132531605 hasRelatedWork W2359425528 @default.
• W3132531605 hasRelatedWork W2378785636 @default.
• W3132531605 hasRelatedWork W2530185749 @default.
• W3132531605 hasRelatedWork W2596000028 @default.
• W3132531605 hasRelatedWork W2999392595 @default.
• W3132531605 hasRelatedWork W3149366977 @default.
• W3132531605 hasRelatedWork W4304116770 @default.
• W3132531605 hasVolume "81" @default.
• W3132531605 isParatext "false" @default.
• W3132531605 isRetracted "false" @default.
• W3132531605 magId "3132531605" @default.
• W3132531605 workType "article" @default.